Distribution of hepatitis G viremia and antibody response to recombinant proteins with special regard to risk factors in 709 patients

被引:60
作者
Feucht, HH
Zollner, B
Polywka, S
Knodler, B
Schroter, M
Nolte, H
Laufs, R
机构
[1] UNIV HAMBURG, HOSP EPPENDORF, DEPT TRANSFUS MED, D-20246 HAMBURG, GERMANY
[2] HOSP PINNEBERG, DEPT MED, PINNEBERG, GERMANY
关键词
D O I
10.1002/hep.510260234
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
A new virus named hepatitis G virus (HGV) has been detected recently. Until now, no assays for the detection of antibodies against different HGV proteins have been commercially available. Therefore, a strip immunoblot assay has been established to investigate seroreactivity against recombinant structural (core) and nonstructural proteins (NS3 and NS4) of HGV produced in Escherichia coli. Seropositivity for HGV was evaluated and concordanced with HGV polymerase chain reaction (PCR) results in 709 subjects, These individuals were classified into a nonrisk or a risk group, on the basis of infection with human immunodeficiency virus (HIV) or hepatitis C virus (HCV) or frequent parenteral exposure, including hemophilia, intravenous drug addiction, receipt of blood transfusion, or hemodialysis. The nonrisk group consisted of 257 healthy blood donors with normal alanine transaminase (AIT) levels (ALT < 30 U/L) and 154 patients with suspected non-A-E hepatitis (ALT > 45 U/L), In the group of healthy blood donors, 1.9% (5 of 257) had detectable HGV viremia and 15.9% (41 of 257) showed antibody response to HGV. In the collective of patients with suspected non-A-E hepatitis, results from 1,9% of patients (3 of 154) were positive by HGV PCR, and 15.6% of patients (24 of 154) showed seropositivity against the recombinant HGV proteins. In six groups of patients (n = 298) with different risk factors, the prevalence of both HGV viremia (V) and serological reactivity (SR) was higher compared with that of the nonrisk group: V, 6.8%-35.2%; serological reactivity (SR), 24.4%-52.9%. The following conclusions can be derived from our data, HGV infection is widespread in the general population. The prevalence of antibodies against HGV or detectable HGV viremia is higher in patients with risk factors for parenteral viral transmission than in those without risk factors, The majority of HGV infections (70.2%) is self-limiting and not persistent in our collective of patients. We found no correlation between HGV viremia and clinical or biochemical signs of hepatitis in individuals without risk factors for acquiring parenterally transmitted agents.
引用
收藏
页码:491 / 494
页数:4
相关论文
共 29 条
[1]   THE NATURAL-HISTORY OF COMMUNITY-ACQUIRED HEPATITIS-C IN THE UNITED-STATES [J].
ALTER, MJ ;
MARGOLIS, HS ;
KRAWCZYNSKI, K ;
JUDSON, FN ;
MARES, A ;
ALEXANDER, WJ ;
HU, PY ;
MILLER, JK ;
GERBER, MA ;
SAMPLINER, RE ;
MEEKS, EL ;
BEACH, MJ .
NEW ENGLAND JOURNAL OF MEDICINE, 1992, 327 (27) :1899-1905
[2]   GENETIC ORGANIZATION AND DIVERSITY OF THE HEPATITIS-C VIRUS [J].
CHOO, QL ;
RICHMAN, KH ;
HAN, JH ;
BERGER, K ;
LEE, C ;
DONG, C ;
GALLEGOS, C ;
COIT, D ;
MEDINASELBY, A ;
BARR, PJ ;
WEINER, AJ ;
BRADLEY, DW ;
KUO, G ;
HOUGHTON, M .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1991, 88 (06) :2451-2455
[3]   PREVALENCE AND EPIDEMIOLOGIC CHARACTERISTICS OF HEPATITIS-C IN SCOTTISH BLOOD-DONORS [J].
CRAWFORD, RJ ;
GILLON, J ;
YAP, PL ;
BROOKES, E ;
MCOMISH, F ;
SIMMONDS, P ;
DOW, BC ;
FOLLETT, EAC .
TRANSFUSION MEDICINE, 1994, 4 (02) :121-124
[4]   DETECTION OF ANTIBODIES TO HEPATITIS-C VIRUS IN UNITED-STATES BLOOD-DONORS [J].
DAWSON, GJ ;
LESNIEWSKI, RR ;
STEWART, JL ;
BOARDWAY, KM ;
GUTIERREZ, RA ;
PENDY, L ;
JOHNSON, RG ;
ALCALDE, X ;
ROTE, KV ;
DEVARE, SG ;
ROBEY, WG ;
PETERSON, DA .
JOURNAL OF CLINICAL MICROBIOLOGY, 1991, 29 (03) :551-556
[5]  
DAWSON GJ, 1996, 9 TRIENN INT S VIR H
[6]   GB virus C infection and liver transplantation: Increased risk of transfusion-transmitted infection [J].
Feucht, HH ;
Fischer, L ;
Sterneck, M ;
Knodler, B ;
Broelsch, CE ;
Laufs, R .
BLOOD, 1997, 89 (06) :2223-2224
[7]   STUDY ON RELIABILITY OF COMMERCIALLY AVAILABLE HEPATITIS-C VIRUS-ANTIBODY TESTS [J].
FEUCHT, HH ;
ZOLLNER, B ;
POLYWKA, S ;
LAUFS, R .
JOURNAL OF CLINICAL MICROBIOLOGY, 1995, 33 (03) :620-624
[8]  
Feucht HH, 1996, LANCET, V347, P615, DOI 10.1016/S0140-6736(96)91309-4
[9]   GREATER AMOUNT OF HCV-RNA IN TEARS COMPARED TO BLOOD [J].
FEUCHT, HH ;
POLYWKA, S ;
ZOLLNER, B ;
LAUFS, R .
MICROBIOLOGY AND IMMUNOLOGY, 1994, 38 (02) :157-158
[10]   TEAR FLUID OF HEPATITIS-C VIRUS CARRIERS COULD BE INFECTIOUS [J].
FEUCHT, HH ;
ZOLLNER, B ;
SCHROTER, M ;
ALTROGGE, H ;
LAUFS, R .
JOURNAL OF CLINICAL MICROBIOLOGY, 1995, 33 (08) :2202-2203